| Name | Title | Contact Details |
|---|
Veterans Evaluation Services is a company that supports the U.S. Department of Veterans Affairs in providing veterans and transitioning service members with the benefits theyve earned through their service to the country. They provide high quality, ti...
Meadowbrook Medical Care is a Bellaire, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Children’s of Alabama has provided specialized medical care for ill and injured children across the state and throughout the southeastern U.S. since 1911. For the past three years, Children’s has been ranked among the best children’s hospital programs in the nation by US News & World Report. Last year, patients made more than 634,000 outpatient and nearly 14,000 inpatient visits to Children’s from every county in Alabama and from 47 other states. With more than 2 million square feet, it is the third largest pediatric medical facility in the U.S. Children’s offers inpatient and outpatient services across its Russell Campus on Birmingham’s historic Southside with additional outpatient services provided at Children’s South and Children’s on 3rd. Primary care is provided at more than a dozen offices in communities across central and north Alabama. The Benjamin Russell Hospital for Children is the only hospital in Alabama dedicated solely to the care and treatment of children. It is a private, not-for-profit hospital that serves as the primary site of the University of Alabama at Birmingham (UAB) pediatric medicine, surgery, research and residency programs.
Cass County Memorial Hospital is a 43-bed hospital located in Atlantic, Iowa. Since 1903, CCMH has cared for the people of southwest Iowa. Certified as a critical access hospital, CCMH staffs 25 acute, 10 distinct skilled, and 8 behavioral health beds.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.